Appendix D: Supplemental Information

Actualizado Reviewed

Table A. Likelihood of Developing AIDS or Death Within 12 Months, by Age and CD4 T-Cell Percentage or Log10 HIV-1 RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy
CD4 Percentage Log10 HIV RNA Copy Number
Age 10% 20% 25% 30% 6.0 5.0 4.0
Percent Mortality (95% Confidence Interval)
6 Months 28.7 12.4 8.5 6.4 9.7 4.1 2.7
1 Year 19.5 6.8 4.5 3.3 8.8 3.1 1.7
2 Years 11.7 3.1 2.0 1.5 8.2 2.5 1.1
5 Years 4.9 0.9 0.6 0.5 7.8 2.1 0.7
10 Years 2.1 0.3 0.2 0.2 7.7 2.0 0.6
Percent Developing AIDS (95% Confidence Interval)
6 Months 51.4 31.2 24.9 20.5 23.7 13.6 10.9
1 Year 40.5 20.9 15.9 12.8 20.9 10.5 7.8
2 Years 28.6 12.0 8.8 7.2 18.8 8.1 5.3
5 Years 14.7 4.7 3.7 3.1 17.0 6.0 3.2
10 Years 7.4 2.2 1.9 1.8 16.2 5.1 2.2
Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study Group. Lancet. 2003;362:1605-1611.

Table B. Death and AIDS/Death Rate per 100 Person-Years by Current Absolute CD4 Cell Count and Age in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy (HIV Paediatric Prognostic Markers Collaborative Study) and Adult Seroconverters (CASCADE Study)
Age (Years) Absolute CD4 Cell Count (cells/mm3)
<50 50–99 100–199 200–349 350–499 500+
Rate of Death Per 100 Patient-Years
0–4 59.3 39.6 25.4 11.1 10.0 3.5
5–14 28.9 11.8 4.3 0.89 0.00 0.00
15–24 34.7 6.1 1.1 0.71 0.58 0.65
25–34 47.7 10.8 3.7 1.1 0.38 0.22
35–44 58.8 15.6 4.5 0.92 0.74 0.85
45–54 66.0 18.8 7.7 1.8 1.3 0.86
55+ 91.3 21.4 17.6 3.8 2.5 0.91
Rate of AIDS or Death per 100 Patient-Years
0–4 82.4 83.2 57.3 21.4 20.7 14.5
5–14 64.3 19.6 16.0 6.1 4.4 3.5
15–24 61.7 30.2 5.9 2.6 1.8 1.2
25–34 93.2 57.6 19.3 6.1 2.3 1.1
35–44 88.1 58.7 25.5 6.6 4.0 1.9
45–54 129.1 56.2 24.7 7.7 3.1 2.7
55+ 157.9 42.5 30.0 10.0 5.1 1.8
Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. J Infect Dis. 2008;197:398-404.

Table C. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4 T-Cell Percentage with Long-Term Risk of Death in HIV-Infected Childrena
Baseline HIV RNAc (Copies/mL)
Baseline CD4 Percentage		 No. Patientsd Deathsb
Number Percentage
≤100,000
≥15% 103 15 (15%)
<15% 24 15 (63%)
>100,000
≥15% 89 32 (36%)
<15% 36 29 (81%)
a Data from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

b Mean follow-up: 5.1 years.

c Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

d Mean age: 3.4 years.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175(5):1029–1038.

Figure A. Estimated Probability of AIDS Within 12 Months by Age and CD4 Percentage in HIV- Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure A. Estimated Probability of AIDS Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure modified from Lancet 2003;362:1605-1611
Figure B. Estimated Probability of Death Within 12 Months by Age and CD4 Percentage in HIV- Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure B. Estimated Probability of Death Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure modified from Lancet 2003;362:1605-1611
Figure C. Death Rate per 100 Person-Years in HIV-Infected Children Aged 5 Years or Older in the HIV Paediatric Prognostic Marker Collaborative Study and HIV-Infected Seroconverting Adults from the CASCADE Study*

Figure C. Death Rate per 100 Person-Years in HIV-Infected Children Aged 5 Years or Older in the HIV Paediatric Prognostic Marker Collaborative Study and HIV-Infected Seroconverting Adults from the CASCADE Study

Figure modifed from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. J Infect Dis. 2008;197:398-404.
Figure D. Estimated Probability of AIDS Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure D. Estimated Probability of AIDS within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure modified from Lancet 2003;362:1605-1611
Figure E. Estimated Probability of Death Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure E. Estimated Probability of Death Within 12 Months by Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

Figure modified from Lancet 2003;362:1605-1611

Table A. Likelihood of Developing AIDS or Death Within 12 Months, by Age and CD4 T-Cell Percentage or Log10 HIV-1 RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy
CD4 Percentage Log10 HIV RNA Copy Number
Age 10% 20% 25% 30% 6.0 5.0 4.0
Percent Mortality (95% Confidence Interval)
6 Months 28.7 12.4 8.5 6.4 9.7 4.1 2.7
1 Year 19.5 6.8 4.5 3.3 8.8 3.1 1.7
2 Years 11.7 3.1 2.0 1.5 8.2 2.5 1.1
5 Years 4.9 0.9 0.6 0.5 7.8 2.1 0.7
10 Years 2.1 0.3 0.2 0.2 7.7 2.0 0.6
Percent Developing AIDS (95% Confidence Interval)
6 Months 51.4 31.2 24.9 20.5 23.7 13.6 10.9
1 Year 40.5 20.9 15.9 12.8 20.9 10.5 7.8
2 Years 28.6 12.0 8.8 7.2 18.8 8.1 5.3
5 Years 14.7 4.7 3.7 3.1 17.0 6.0 3.2
10 Years 7.4 2.2 1.9 1.8 16.2 5.1 2.2
Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study Group. Lancet. 2003;362:1605-1611.

Table B. Death and AIDS/Death Rate per 100 Person-Years by Current Absolute CD4 Cell Count and Age in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy (HIV Paediatric Prognostic Markers Collaborative Study) and Adult Seroconverters (CASCADE Study)
Age (Years) Absolute CD4 Cell Count (cells/mm3)
<50 50–99 100–199 200–349 350–499 500+
Rate of Death Per 100 Patient-Years
0–4 59.3 39.6 25.4 11.1 10.0 3.5
5–14 28.9 11.8 4.3 0.89 0.00 0.00
15–24 34.7 6.1 1.1 0.71 0.58 0.65
25–34 47.7 10.8 3.7 1.1 0.38 0.22
35–44 58.8 15.6 4.5 0.92 0.74 0.85
45–54 66.0 18.8 7.7 1.8 1.3 0.86
55+ 91.3 21.4 17.6 3.8 2.5 0.91
Rate of AIDS or Death per 100 Patient-Years
0–4 82.4 83.2 57.3 21.4 20.7 14.5
5–14 64.3 19.6 16.0 6.1 4.4 3.5
15–24 61.7 30.2 5.9 2.6 1.8 1.2
25–34 93.2 57.6 19.3 6.1 2.3 1.1
35–44 88.1 58.7 25.5 6.6 4.0 1.9
45–54 129.1 56.2 24.7 7.7 3.1 2.7
55+ 157.9 42.5 30.0 10.0 5.1 1.8
Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. J Infect Dis. 2008;197:398-404.

Table C. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4 T-Cell Percentage with Long-Term Risk of Death in HIV-Infected Childrena
Baseline HIV RNAc (Copies/mL)
Baseline CD4 Percentage		 No. Patientsd Deathsb
Number Percentage
≤100,000
≥15% 103 15 (15%)
<15% 24 15 (63%)
>100,000
≥15% 89 32 (36%)
<15% 36 29 (81%)
a Data from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

b Mean follow-up: 5.1 years.

c Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

d Mean age: 3.4 years.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175(5):1029–1038.

Download Guidelines

Related Content